Sonoma Pharmaceuticals, Inc. (SNOA) - 10-Q Summary
Business Context and Reporting Period
Company: Sonoma Pharmaceuticals, Inc.
Reporting Period: Quarter ended December 31, 2025 (Q3 Fiscal 2026) and Nine Months ended December 31, 2025.
Business Overview: A global healthcare leader developing and producing stabilized hypochlorous acid (HOCl) products for wound care, eye care, dermatology, podiatry, animal health, and disinfection. Products are sold directly and via partners in over 55 countries.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenues | $4,349 | $3,564 | $13,968 | $10,534 |
| Gross Profit | $1,650 | $1,270 | $5,234 | $3,937 |
| Gross Margin | 38% | 36% | 37% | 37% |
| Net Loss | $(819) | $(928) | $(2,594) | $(2,681) |
| Net Loss Per Share (Basic/Diluted) | $(0.48) | $(0.63) | $(1.56) | $(2.40) |
| Cash and Equivalents (End of Period) | $2,561 | $5,236 | $2,561 | $5,236 |
| Working Capital | $7,928 | $8,677 | $7,928 | $8,677 |
| Short-Term Debt | $0 | $220 | $0 | $220 |
Note: All financial figures are in thousands unless otherwise noted. The company reported a net loss for all periods presented.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 22% in Q3 and 33% over the nine-month period compared to the prior year.
- United States: Revenue surged 98% in Q3 and 90% over nine months, driven by increased sales of over-the-counter products and new distributor relationships.
- Europe: Revenue grew 24% in Q3 and 31% over nine months due to increased product demand.
- Asia: Revenue increased 38% in both periods.
- Latin America: Revenue declined 38% in Q3 and 26% over nine months, attributed to the timing of customer orders for overflow manufacturing.
- Profitability: While the company remains unprofitable, the net loss narrowed in Q3 ($819k vs $928k) and the nine-month period ($2.59M vs $2.68M). Gross margin improved slightly in Q3 to 38% from 36%.
- Operating Expenses:
- R&D: Increased 30% in Q3 and 23% over nine months to support new product releases.
- SG&A: Decreased 5% in Q3 ($1.77M vs $1.87M) due to cost control efforts, though it remained relatively flat (+1%) over the nine-month period.
- Cash Flow: Net cash used in operating activities was $3.41M for the nine months ended Dec 31, 2025, compared to a negligible $7k provided in the prior year. This was driven by the net loss, increased inventory ($484k), and prepaid expenses ($1.23M).
- Debt: The company paid off its short-term debt of $220k related to insurance premium financing during the period; no short-term debt remains as of Dec 31, 2025.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management explicitly states there is "substantial doubt" about the company's ability to continue as a going concern within one year due to the history of losses and the need for additional capital. The financial statements do not include adjustments that might be necessary if the company cannot continue operations.
- Liquidity Strategy: The company relies on cash on hand, equity offerings (sold 80,848 shares for net proceeds of $266k in Q3), and employee retention credits ($619k recognized). Management believes access to additional capital exists but cannot guarantee terms.
- Tax Liability: The company faces a substantial Mexico tax liability, intercompany debt, and accrued interest due in 2027. Management believes current assets are sufficient to cover this without interrupting operations.
- Customer Concentration: Revenue is concentrated among a few key customers. Customer C accounted for 25% of Q3 revenue and 20% of nine-month revenue. Customer B accounted for 12% in both periods.
- Recent Developments:
- Entered a Master Supply Agreement with WellSpring Pharmaceutical Corporation for large U.S. retailers.
- Entered a distribution agreement with Medline Industries, LP for wound care products in the U.S. and Canada.
- Subsequent events include new equity grants to directors and employees in January 2026 and the appointment of a new director.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.56M cash balance against the $3.41M operating cash burn rate over nine months to assess immediate liquidity risk.
- Capital Raising: Monitor upcoming equity offerings or debt financings required to sustain operations given the "substantial doubt" disclosure.
- Customer Dependency: Assess the risk associated with Customer C representing 20-25% of total revenue.
- International Tax Exposure: Review the status of the substantial Mexico tax liability and intercompany debt due in 2027.
- Revenue Quality: Analyze the sustainability of the 98% U.S. revenue growth, specifically regarding the new distributor agreements with WellSpring and Medline.